These guidelines, issued by the American Society for Blood and Marrow Transplantation (ASBMT), identify established indications for autologous and allogeneic hematopoietic cell transplantation (HCT), and make recommendations on emerging indications where HCT may be beneficial. The guidelines place indications into five categories, ranging from (1) Standard of care, where indication for HCT is well defined and supported by evidence, to (5) Not generally recommended, where available evidence does not support the routine use of HCT. The recommendations are based on best available evidence from clinical trials or, where clinical trials are not available, registry, multi-center or single-center observational studies.
Majhail NS, et al. Biol Blood Marrow Transplant